As an expert in the field of antibody discovery, Creative Biolabs is able to offer high-quality in vitro diagnostic (IVD) antibody development services for customers across the world. With years of experience, our scientists have developed an advanced platform for IVD antibody discovery against various markers of multiple diseases. Here, we focus on the profilin 1 (PFN1) marker for bladder cancer diagnosis.
PFN1 is a 15 kDa protein, ubiquitously expressed in mammalian cells, which was found highly expressed in our gene expression profiling (GEP) data of multiple myeloma (MM). It is thought to be a key regulator of actin polymerization in cells. PFN1 can bind actin with ATP and ADP, which maintains the speed of actin polymerization during the elongation of new filaments by controlling the exchange of binding with ATP and ADP. It also has two other domains that can bind the poly-I-proline (PLP) domain and PIP2 or PIP3. PLP domain of PFN1 can bind other cytoskeleton proteins, which engages in general motility functions, such as cell migration, cytokinesis, membrane trafficking and endocytosis in all cell types.
Fig.1 Integrated scheme of functional signaling mechanisms mediating radial lamellipodia formation and myelination downstream of the IPP complex and of β1 integrin. (Montani, L., 2014)
Profilins (PFNs) constitute a group of evolutionarily conserved small actin-binding proteins that serve regulatory roles in many cellular activities, including proliferation and motility. PFN1, the founding member of the family, has been linked to several types of human carcinomas. For example, in pancreatic cancer, PFN1 is downregulated in clinical tumor tissues, and overexpression of PFN1 can impair the malignant phenotypes of tumor cells. In addition, PFN1 overexpression increases the sensitivity of breast cancer cells to camptothecin-induced apoptosis. Especially, studies have found that the expression level of PFN1 in patients with bladder cancer is down-regulated than that of healthy people. In this case, PFN1 can be treated as a potential biomarker for bladder cancer diagnosis.
In the past decades, IVD antibodies have been extensively used in different immunoassays for disease screening and therapeutic monitoring. As a leading company in IVD antibody development, Creative Biolabs is dedicated to delivering a full package of IVD antibody development services with the highest quality for the diagnosis and prognosis of multiple diseases. With our versatile IVD platform, Creative Biolabs is proud to develop novel PFN1-specific (paired) antibodies from scratch to commercial IVD kit (we can also start with provided antibody candidates).
Creative Biolabs has focused on IVD antibody discovery for years. We have experts who are able to develop high-affinity IVD antibodies against numerous markers. We are therefore confident in offering the most suitable service and finest results for our customers all over the world. If you are interested in our services, please feel free to contact us for more details or directly send us an inquiry.
Reference
For Research Use Only.
